doc_id,table_id,row_index,ColumnA,ColumnB,ColumnC,ColumnD,ColumnE
WHO_TB_handbook_module4_treatment_2025,Table 2.9.3.,1,Activity,3 months post- end- o f treatment,6 months post- end-of treatment,9 months post- end-of treatment,12 months post- end-of treatment
WHO_TB_handbook_module4_treatment_2025,Table 2.9.3.,2,"In-person clinic visit ( The clinical visit should consist of the weight, BMI, and brief peripheral neuropathy screen as well as any other clinical and laboratory examination needed based on symptoms) or telephone contact ( Telephone contact is acceptable only when it is not feasible for the patient to come for an in-person clinic visit. Discuss directly with the patient only, unless permission has been granted to discuss the patientâ€™s illness with a family member or health proxy)",X,X,X,X
WHO_TB_handbook_module4_treatment_2025,Table 2.9.3.,3,Monitoring smear and culture (done regardless of signs of recurrence being present),If indicated,X,If indicated,X
WHO_TB_handbook_module4_treatment_2025,Table 2.9.3.,4,Chest X-ray,If indicated,If indicated,If indicated,If indicated
WHO_TB_handbook_module4_treatment_2025,Table 2.9.3.,5,Any positive culture in the post-treatment period,Conduct resistance testing for all drugs,Conduct resistance testing for all drugs,Conduct resistance testing for all drugs,Conduct resistance testing for all drugs